Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track EOLS with free AI briefings, catalyst countdowns, and dilution alerts.

EOLS · Evolus, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$41.7M Cash on Hand
45.3mo Cash Runway
Follow EOLS by email Get an email when EOLS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about EOLS, unsubscribe in one click. Privacy

📣 What EOLS Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Prabotulinum Toxin Type A Neck Muscle Issue Phase 4 · NCT06903975 Recruiting
Botulinum purified neurotoxin, Type A Glabellar Frown Lines Phase 2 · NCT02184988 Completed
DWP-450 (Botulinum purified neurotoxin, Type A)… Glabellar Frown Lines Phase 2 · NCT02428608 Completed

Also used in these trials (approved or third-party drugs, not EOLS's own candidates): Botulinum Toxin Type A, Onabotulinumtoxina, Incobotulinumtoxina.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

EOLS holds $41.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $2.8M/quarter from operations, an estimated runway of 45.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 10 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when EOLS files for a raise →

👥 Who Owns EOLS

Insiders 4.1% Other 5%+ holders 9.7% Institutions (212 holders) 80.1% Public and other holders 6.1%
HolderTypeShares% of sharesAs of
Timothy P. Lynch 5%+ holder (13G) 6,425,726 9.71% 2025-12-31
Soleus Capital Master Fund, L.P. Institution (13G, 5%+) 5,090,000 7.69% 2026-09-30
Simone Blank
Director · +11,146 options
Insider 559,894 0.85% 2025-03-07
David Moatazedi
President and Chief Executive Officer, D · +660,954 options
Insider 499,592 0.75% 2026-09-02
Rui Avelar
Officer · +181,326 options
Insider 427,423 0.65% 2026-03-20
Vikram Malik
Director · +11,146 options
Insider 321,109 0.49% 2026-02-17
Tatjana Mitchell
Chief Financial Officer · +442,363 options
Insider 226,092 0.34% 2026-02-17
Sandra Beaver
Chief Financial Officer · +86,476 options
Insider 167,089 0.25% 2025-05-13
Brady Stewart
Director · +11,146 options
Insider 134,188 0.20% 2026-02-17
Albert G III White
Director · +11,146 options
Insider 95,937 0.14% 2026-02-17
Tomoko Yamagishi-Dressler
Chief Marketing Officer · +43,239 options
Insider 89,949 0.14% 2025-08-22
David N Gill
Director · +11,146 options
Insider 86,887 0.13% 2026-02-17

Share count 66,188,366 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full EOLS picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for EOLS and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.